227 related articles for article (PubMed ID: 7586928)
1. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
2. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
4. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
5. Affinities of dihydrocodeine and its metabolites to opioid receptors.
Schmidt H; Vormfelde Sv; Klinder K; Gundert-Remy U; Gleiter CH; Skopp G; Aderjan R; Fuhr U
Pharmacol Toxicol; 2002 Aug; 91(2):57-63. PubMed ID: 12420793
[TBL] [Abstract][Full Text] [Related]
6. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
7. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.
Wilder-Smith CH; Hufschmid E; Thormann W
Br J Clin Pharmacol; 1998 Jun; 45(6):575-81. PubMed ID: 9663813
[TBL] [Abstract][Full Text] [Related]
8. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
11. The role of active metabolites in dihydrocodeine effects.
Schmidt H; Vormfelde SV; Walchner-Bonjean M; Klinder K; Freudenthaler S; Gleiter CH; Gundert-Remy U; Skopp G; Aderjan R; Fuhr U
Int J Clin Pharmacol Ther; 2003 Mar; 41(3):95-106. PubMed ID: 12665158
[TBL] [Abstract][Full Text] [Related]
12. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
13. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydromorphine by micellar electrokinetic capillary chromatography.
Hufschmid E; Theurillat R; Wilder-Smith CH; Thormann W
J Chromatogr B Biomed Appl; 1996 Mar; 678(1):43-51. PubMed ID: 8861655
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.
Ammon S; Hofmann U; Griese EU; Gugeler N; Mikus G
Br J Clin Pharmacol; 1999 Sep; 48(3):317-22. PubMed ID: 10510141
[TBL] [Abstract][Full Text] [Related]
17. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
18. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
